Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products is continuously evaluated. When important safety issues arise, if applicable, we promptly notify healthcare the professionals, patients and regulatory agencies concerned in accordance with current legislation.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem (Ref. World Health Organization, WHO. The importance of pharmacovigilance: safety monitoring of medicinal products, Genève, WHO, 2002).
In line with this general definition, the main objectives of pharmacovigilance in accordance with the applicable EU legislation are:
Pharmacovigilance is therefore an activity contributing to the protection of patient and public health.
A response to a medicinal product which is harmful and unintended (response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility).
Adverse reactions may arise from use of the product within or outside the terms of the marketing authorisation or from occupational exposure. Conditions of use outside the marketing authorisation include off-label use, overdose, misuse, abuse and medication errors.
Report of adverse events and/or product defects
Tel. +40212023642
Fax +40212023643
Email medinfo.ro(at)chiesi.com
Please consider that your mail will be processed during office hours.
After office hours please call our hotline: Tel. +40 737 99 50 29
Chiesi Farmaceutici S.p.A. is an international, privately-owned pharmaceutical company based in Parma, Italy. Chiesi dedicates itself to the research, development and sales of innovative medicines in the areas of respiratory, neonatology, transplant, rare diseases and others.